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Abstract
Background  and  objectives: Tenoxicam  is  widely  used  in  osteoarthritis  treatment  and  we  aimed
to compare  the  effectivity  of  oral  and  intra-articular  administration  of  tenoxicam  in  osteoarthri-
tis treatment.
Methods:  This  study  was  performed  between  2011  and  2012  by  retrospectively  analyzing  and
comparing  the  ﬁndings  of  60  patients  who  were  clinically  and  radiologically  diagnosed  with  knee
degenerative  osteoarthritis  in  Bünyan  state  hospital  pain  policlinic.  60  patients  included  in  the
study were  divided  into  two  groups.  The  ﬁrst  group  (tenoxicam  IA,  n  =  30)  included  patient
ﬁndings of  those  subjected  to  intra-articular  injection  of  20  mg  tenoxicam  to  the  knee  once
a week  for  three  weeks  and  the  second  group  (oral  tenoxicam,  n  =  30)  included  patients  who
were administered  20  mg  oral  tenoxicam  once  a  day  for  three  weeks.  All  patients  were  clini-
cally evaluated  pre-treatment  and  in  the  1st  week,  1st  month  and  3rd  month  post-treatment
according  to  speciﬁed  criteria.
Results  and  conclusions:  Twenty  two  of  60  patients  included  in  the  study  were  male  and  38
were female.  In  both  groups  signiﬁcant  improvements  were  detected  in  all  of  the  observed
parameters:  visual  analog  scale,  Western  Ontario  McMaster  Osteoarthritis  Index  (pain,  physical
activity,  knee  stiffness)  and  Lequesne  index  scores  and  in  the  evaluations  performed  in  1st  week,
1st month  and  3rd  month  with  respect  to  pre-treatment  values.  Besides,  a  better  compliance
to treatment  and  gastrointestinal  system  tolerability  in  tenoxicam  IA  group  was  also  observed.
Intra-articular  tenoxicam  administration  could  be  thought  as  an  alternative  treatment  method
in patients  with  knee  osteoarthritis  who  cannot  use  oral  tenoxicam  especially  due  to  systemic
gastrointestinal  system  side  effects  and  those  who  have  difﬁculties  in  adapting  to  treatment.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.∗ Corresponding author.
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Comparac¸ão  da  eﬁcácia  de  tenoxicam  administrado  por  via  oral  e  intra-articular  a
pacientes  com  osteoartrite  de  joelhos
Resumo
Justiﬁcativa  e  objetivos:  Tenoxicam  é  amplamente  usado  no  tratamento  da  osteoartrite  (OA)
e o  nosso  objetivo  foi  comparar  a  eﬁcácia  de  tenoxicam  administrado  por  via  oral  (VO)  e  intra-
articular (IA)  no  tratamento  da  OA.
Métodos:  Este  estudo  foi  conduzido  entre  2011  e  2012  por  meio  de  análise  retrospectiva  e
comparac¸ão dos  resultados  de  60  pacientes  que  foram  clínica  e  radiologicamente  diagnosticados
com OA  degenerativa  de  joelhos  na  Policlínica  de  Tratamento  da  Dor  do  Hospital  Estadual  de
Bünyan. Os  60  pacientes  incluídos  no  estudo  foram  alocados  em  dois  grupos.  O  primeiro  grupo
(tenoxicam  IA,  n  =  30)  incluiu  resultados  de  pacientes  submetidos  à  injec¸ão  nos  joelhos  por
via IA  de  20  mg  de  tenoxicam  uma  vez  por  semana  durante  três  semanas  e  o  segundo  grupo
(tenoxicam  VO,  n  =  30)  incluiu  pacientes  que  receberam  20  mg  de  tenoxicam  por  VO  uma  vez
por dia  durante  três  semanas.  Todos  os  pacientes  foram  avaliados  clinicamente  na  fase  basal
pré-tratamento  e  em  uma  semana,  um  mês  e  três  meses  pós-tratamento,  de  acordo  com  os
critérios especiﬁcados.
Resultados  e  conclusões:  Dos  60  pacientes,  22  eram  do  sexo  masculino  e  38  do  sexo  feminino.
Em ambos  os  grupos,  melhorias  signiﬁcativas  foram  detectadas  em  todos  os  parâmetros  da  escala
visual analógica,  do  índice  Western  Ontario  and  MacMaster  (Womac  --  dor,  atividade  física  e
rigidez dos  joelhos)  e  do  índice  de  Lequesne  nas  avaliac¸ões  feitas  em  uma  semana,  um  mês  e
três meses  e  comparadas  aos  valores  basais.  Além  disso,  uma  melhor  adesão  ao  tratamento  e
tolerabilidade  ao  sistema  gastrointestinal  no  grupo  tenoxicam  IA  também  foram  observadas.  A
administrac¸ão de  tenoxicam  IA  pode  ser  considerada  como  um  método  opcional  de  tratamento
em pacientes  com  OA  de  joelhos  que  não  podem  usar  tenoxicam  por  VO,  especialmente  por
causa dos  efeitos  colaterais  sobre  o  sistema  gastrintestinal,  e  naqueles  com  diﬁculdades  de
adaptac¸ão ao  tratamento.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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steoarthritis  (OA)  is  the  arthritis  form  most  commonly
ncountered  in  the  world.  OA  is  primarily  deﬁned  as
 repair  process  developed  against  joint  degeneration
nd  joint  destruction  that  cause  a  series  of  biochemical
nd  morphologic  changes  in  joint  capsule  and  synovial  mem-
rane  and  against  erosion  in  joint  cartilage,  osteophytic
ypertrophy  of  bones  in  joint  edges,  subchondral  sclerosis.1
A  is  especially  one  of  the  leading  causes  of  morbidity
hat  affects  life  quality  of  geriatric  patients  negatively.  Pain
s  the  most  encountered  and  the  most  important  symp-
om.  OA  pain  is  complicated  and  complex.  Tissues  other
han  cartilage  in  the  joint  have  a  rich  nociceptive  net.
A  treatment  should  be  conducted  with  pharmacological
nd  non-pharmacological  method.  The  primary  aim  in  OA
reatment  is  to  stop  the  pain;  mainly  acetaminophen  and
SAI  drugs  are  used  for  this  purpose.  But  the  physicians
ry  to  develop  new  treatment  alternatives  because  the
bove  stated  treatment  options  remain  inadequate  and  side
ffects  develop  in  the  long  term.2,3 Analgesics  and  NSAI
Nonsteroidal  anti-inﬂammatory)  drugs  are  widely  used  in
A  treatment.  But  care  should  be  taken  in  the  administra-
ion  of  these  drugs  in  elderly  patients  due  to  their  serious
ide  effects  and  the  weakness  of  their  effectivity.4 They
ust  reach  a  speciﬁc  concentration  in  the  blood  for  anti-
nﬂammatory  characteristics  of  NSAI  drugs  to  appear  and  but
heir  potential  side  effects  cause  patients  to  decrease  the
l
w
e
gose  they  use  and  generally  effective  dose  concentration
annot  be  reached.  Tenoxicam  is  widely  used  in  OA  treat-
ent.  Furthermore  it  is  shown  that  intra-articular  injection
f  tenoxicam  is  commonly  used  in  OA  treatment  and  has
eneﬁcial  effects.5
With  this  study  we  estimated  that  IA  tenoxicam  treat-
ent  in  patients  with  OA  provided  a  more  effective
reatment  than  oral  tenoxicam  (TXO),  with  less  side  effects.
ethods
his  study  was  performed  by  retrospectively  analyzing  and
omparing  ﬁndings  of  60  patients  diagnosed  clinically  and
adiologically  with  knee  degenerative  OA  in  Bünyan  state
ospital  between  2011  and  2012.  Required  consents  were
btained  from  the  patients  by  explaining  them  the  disease
nd  the  treatment  to  be  performed.  Consent  of  C¸anakkale
8  Mart  University  Clinical  Research  Ethics  Committee  was
lso  obtained  (15.05.2013/11-08;  Aksulu  HA).  Data  of  50--80
ears  old  patients  in  ASA  I--III  group  were  included  in  the
tudy.
OA  diagnosis  was  established  following  clinical  story,
adiographic  changes  and  physical  examination.  Radiogra-
hies  of  both  knees,  standing,  frontal  and  posterior  and
ateral  were  taken  from  all  patients.  The  ﬁndings  of  patients
ith  knee  arthritis  according  to  American  Rheumatism  Soci-
ty,  without  any  laboratory  pathology,  between  0  and  III
rade  according  to  Kellgren-Lawrence  classiﬁcation  were
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Table  1  Demographic  characteristics  of  patients.
Group  TXIA  Group  TXO
Age  (year)  65  ±  5.6  66  ±  4.7
Body mass  index  (BMI)  30.9  ±  1.93  30.2  ±  1.31
Duration  of  illness  (month)  16.2  16.9
Table  2  VAS  in  1st  week,  1st  month  and  3rd  month  when
compared  with  pre-treatment  values.
VAS  Group  TXIA  Group  TXO
Baseline  8.2  ±  0.61  8.1  ±  0.54
1st week 2.3  ±  0.49a 2.8  ±  0.48a
1st  month  3.2  ±  0.40a 3.7  ±  0.44a
3rd  month  4.1  ±  0.37a 4.8  ±  0.40a
General  p  value  0.001  0.001
a Differences compared with baseline were statistically signif-
icant (p < 0.001).
Table  3  WOMAC  (pain,  physical  activity,  knee  stiffness)  in
1st week,  1st  month  and  3rd  month  when  compared  with
pre-treatment  values.
WOMAC  score  Group  TXIA  Group  TXO
Pain
Baseline  20.3  ±  0.66  20  ±  0.61
1st week  9.1  ±  0.74a 9.8  ±  0.86a
1st  month  11.4  ±  0.57a 11.4  ±  0.62a
3rd  month  14  ±  0.71a 14.2  ±  0.71a
General  p  value  0.001  0.001
Physical  function
Baseline  68.1  ±  0.83  68.4  ±  0.97
1st week 44  ±  0.99a 45.2  ±  1.22a
1st  month 54.2  ±  1.32a 53.7  ±  1.41a
3rd  month  55.5  ±  1.22a 54.9  ±  1.88a
General  p  value 0.001  0.001
Stiffness
Baseline  8.2  ±  0.66  7.86  ±  0.77
1st week  3.93  ±  0.73a 3.46  ±  0.5a
1st  month  5.26  ±  0.63a 4  ±  0.20a
3rd  month  5.56  ±  0.89a 4.96  ±  0.18a
General  p  value  0.001  0.001
t
D
Signiﬁcant  improvements  were  detected  in  all  the  param-
eters  in  scores  of  VAS,  WOMAC  (pain,  physical  activity,
Table  4  Lequesne  index  in  1st  week,  1st  month  and  3rd
month  when  compared  with  pre-treatment  values.
Lequesne  index  Group  TXIA  Group  TXO
Baseline  13.73  ±  0.52  13.4  ±  0.72
1st week  4.33  ±  0.47a 4.63  ±  0.66a
1st  month  6.80  ±  0.88a 6.53  ±  0.50a
3rd  month 8.03  ±  0.71a 8.33  ±  0.47aASA I/II/III  4/14/12  6/13/11
included  in  the  study.  Sixty  patients,  data  of  which  were
used  in  the  study,  were  divided  into  two  groups.  In  the  ﬁrst
group  (n  =  30)  patients  were  administered  20  mg  tenoxicam
IA  (TXIA)  injection  once  a  week  for  three  weeks.  In  the  sec-
ond  group  (n  =  30),  patients  administered  oral  daily  dosis  of
20  mg  tenoxicam  (TXO)  for  three  weeks.  Furthermore,  phys-
ical  treatment  program  including  rehabilitation,  stretching
and  aerobic  exercises  to  increase  joint  range  of  movement
was  applied  to  all  patients.  All  patients  were  clinically
evaluated  pre-treatment  and  in  the  1st  week,  1st  month
and  3rd  month  post-treatment  according  to  the  speciﬁed
criteria.  According  to  this,  sensation  of  pain  was  evaluated
with  visual  analog  scale  (VAS)  (0:  no  pain,  10:  very  severe
pain).  Furthermore,  pain  status,  functional  capabilities  and
morning  stiffness  of  patients  were  evaluated  according  to
Western  Ontario  McMaster  Osteoarthritis  (WOMAC)  index.
And,  Lequesne  index  was  used  to  evaluate  pain  and  func-
tional  capabilities  of  patients.  Also  complaints  of  patients
associated  with  gastrointestinal  system  (GIS)  (gastritis,  nau-
sea,  epigastric  burning,  constipation)  during  treatment  were
deﬁned  as  GIS  tolerability  and  data  of  compliance  to  treat-
ment  were  recorded.
Statistical  analysis
The  SPSS  software  (SPSS  13,  Chicago,  IL,  USA)  was  used
for  analysis.  Descriptive  parameters  are  presented  as
mean  ±  standard  deviation,  median  (minimum--maximum).
Independent  simple  t  test  was  used  for  comparing  means
of  continuous  variables  between  two  groups.  When  there
were  more  than  two  groups,  Friedman  test  was  used,
Bonferroni  correction  was  used  for  multiple  comparisons
(˛*  =  0.05/6  =  0.0083),  respectively.  A  p-value  of  <0.05  was
considered  as  signiﬁcant.
Results
22  of  60  patients  included  in  the  study  were  male  and
38  were  female.  Demographic  characteristics  of  patients
in  both  groups  were  shown  in  Table  1.  Signiﬁcant  recov-
eries  in  all  the  parameters  were  detected  in  both  groups
in  VAS,  WOMAC  (pain,  physical  activity,  knee  stiffness)  and
Lequesne  index  in  1st  week,  1st  month  and  3rd  month
when  compared  with  pre-treatment  values  (Tables  2--4)
(p  <  0.001).
Signiﬁcant  increases  were  detected  in  all  the  parame-
ters  in  VAS,  WOMAC  (pain,  physical  activity,  knee  stiffness)
and  Lequesne  index  in  the  3rd  month  evaluations  when  com-
pared  with  the  post-treatment  1st  week  values  (p  <  0.001).
But  it  was  observed  that  these  results  remained  lower  than
pre-treatment  values.a Differences compared with baseline were statistically signif-
icant (p < 0.001).
GIS  tolerability  during  the  treatment  and  treatment  con-
inuity  are  shown  in  Table  5.
iscussionGeneral  p  value 0.001 0.001
a Differences compared with baseline were statistically signif-
icant (p < 0.001).
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Table  5  Patients’  adherence  to  treatment  and  GIS
tolerance.
Group  TXIA  Group  TXO
GIS  intolerance  2/30  6/30
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GIS, gastrointestinal system.
nee  stiffness)  and  Lequesne  index  in  1st  week,  1st  month
nd  3rd  month  post-treatment  in  intra-articular  tenoxicam
dministered  patients  for  three  weeks  and  TXO  adminis-
ered  patients  for  the  same  time  when  compared  with  the
re-treatment  values.  An  improvement  in  all  the  param-
ters  in  scores  of  VAS,  WOMAC  (pain,  physical  activity,
nee  stiffness)  and  Lequesne  index  was  observed  in  the  3rd
onth  post-treatment  when  compared  with  the  1st  week
ost-treatment  in  all  the  patients  in  both  groups,  but  this
mprovement  remained  under  the  pre-treatment  values.
Although  NSAI  drugs  are  used  commonly  for  their  anal-
esic  and  anti-inﬂammatory  effects  for  low  to  mild  pain  in
atients  with  knee  OA,  their  systemic  side  effects  limit  their
ong-term  use.  And  therefore  in  the  last  few  years  intra-
rticular  procedures  became  a  current  issue  and  for  this
urpose  intra-articular  NSAID,  corticosteroids,  local  anes-
hetics  or  hyaluronic  acid  preparations  were  used.6--8 But
ecause  hyaluronic  acid  treatment  has  a  high  cost  and  cor-
icosteroid  treatment  is  not  suitable  for  frequent  use,  we
onsider  that  tenoxicam  intra-articular  injection  with  a  low
ost  and  few  side  effects  can  be  used  in  suitable  patients.
All  selective  COX-2  inhibitors  are  contraindicated  to
hose  with  congestive  heart  failure,  ischemic  heart  disease
r  stroke  history.  It  should  be  used  with  caution  in  those  with
ardiovascular  risk  factor  (hypertension,  hyperlipidemia,
iabetes,  cigarette  consumption).9,10 For  this  reason  mini-
um  effective  dose  should  be  used  for  the  shortest  period.
elective  COX-2  inhibitors  are  indicated  in  those  with  high
astrointestinal  risk  and  with  no  cardiovascular  risk.  FDA
emanded  black  box  warning  to  be  put  on  all  NSAID  boxes
nd  also  a  warning  stating  that  it  could  cause  an  increase  in
I  bleeding  and  Cardiovascular  problems  to  be  mentioned.
he  studies  regarding  this  subject  continue.9,10 Most  of  the
atients  in  our  study  had  at  least  one  systemic  disease;  in
ther  words  they  were  ASA  II--III  group  patients.
Although  there  are  some  questions  regarding  the  safety
f  intra-articular  injection  of  NSAI  drugs,  it  is  supposed
hat  tenoxicam  is  safe  in  this  respect.  Especially  in  patients
ubjected  to  arthroscopic  surgery  it  was  administered  intra-
rticularly  in  order  to  provide  post-operative  analgesia.
ntra-artical  tenoxicam  appears  to  be  a  safe  treatment
ethod  for  knee  OA.  But  although  it  is  encountered  rarely,
isks  such  as  bleeding  and  sepsis  should  be  kept  in  mind.11--13
t  is  stated  that  tenoxicam  does  not  affect  prostaglandin
etabolism  in  cartilage  tissue  and  its  effects  on  hyaluronan
ynthesis  vary  depending  on  the  dosage.  And  it  is  indicated
hat  it  inhibits  glycosaminoglycan  loss  in  the  cartilage.14
n  the  comparative  study  between  tenoxicam  and  other
ASID  it  was  shown  that  proteoglycan  and  collagen  syn-
hesis  was  suppressed  by  tenoxicam  and  tenoxicam  could
e  helpful  in  decreasing  cartilage  catabolism  in  patients
ith  OA.15 Intra-articular  use  of  tenoxicam  in  patients  with
A  becomes  increasingly  popular  due  to  its  ease  of  use,M.  Erbas  et  al.
hondroprotective  and  pain  revealing  characteristic.  And
SAI  drugs  should  be  used  with  caution  in  old  patients  due
o  their  systemic  side  effects.  They  increase  bleeding  risk
n  patients  using  anticoagulants.  GIS  should  be  thoroughly
xamined.11,12 In  the  study  we  conducted,  we  observed  that
irect  injection  of  tenoxicam  into  knee  joint  provided  a
ood  alternative  in  patients  who  were  required  to  use  NSAID
ith  regards  to  both  gastrointestinal  tolerability  and  treat-
ent  continuity.  Furthermore,  in  a  study  40  mg  single  dose
enoxicam  was  administered  to  patients  with  polyarthritis
nd  then  concentration  of  drug  in  plasma  and  synovial  liq-
id  were  measured;  half-life  was  42  h  in  the  plasma  and  45  h
n  synovial  liquid.  Thus,  half-life  of  tenoxicam  in  plasma  and
ynovial  liquid  was  shown  to  be  parallel.16
In  a  study  patients  with  OA  were  divided  into  three
roups:  TXO,  TXIA  and  only  exercise  group.  Patients  were
ollowed  for  6  months  and  compared  with  regards  to  func-
ional  capacity  and  pain,  and  no  difference  was  observed
etween  3  groups.5 And  in  another  study,  single  dose  intra-
rticular  injection  of  tenoxicam  was  performed  to  patients
ith  knee  OA.  In  the  evaluations  of  patients  performed  one
onth  later,  40%  decrease  in  pain  and  60%  increase  in  the
oint  movement  aperture  was  observed.12 Our  results  show
hat  intra-articular  tenoxicam  treatment  may  be  preferred
o  TXO  treatment  especially  for  patients  that  cannot  use
rug  in  sufﬁcient  doses  due  to  gastrointestinal  intolerance.
In  patients  with  knee  arthritis  who  cannot  use  TXO
ue  to  systemic,  especially  GIS  side  effects  or  those  who
ave  difﬁculty  in  adapting  to  the  treatment,  intra-articular
enoxicam  treatment  can  be  thought  as  an  alternative  treat-
ent  method.
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